Solstice Advanced Materials Inc. Common Stock
SOLS
$56.16
-0.81%
Solstice Advanced Materials is a diversified specialty chemicals company spun off from Honeywell in late 2025, operating in the Chemicals - Specialty industry. It supplies low global warming potential refrigerants for HVAC and automotive, along with materials for construction, semiconductors, healthcare packaging, and defense, and runs the only operational US uranium conversion facility. As a newly independent entity, the company is positioned as a niche player with a unique asset mix, but it faces the challenge of establishing its own identity and growth trajectory post-spin-off. Investor attention is currently focused on its ability to execute as a standalone company, manage its debt load, and capitalize on regulatory tailwinds for environmentally friendly refrigerants and domestic uranium supply, though recent stock volatility suggests uncertainty about its near-term earnings power.…
SOLS
Solstice Advanced Materials Inc. Common Stock
$56.16
Related headlines
Investment Opinion: Should I buy SOLS Today?
Based on the data, SOLS is rated a Buy with a thesis that the market is undervaluing its earnings growth potential, as evidenced by a forward PE of 16.8x versus trailing 32.6x. The average analyst target of $80.43 implies 43% upside, and the consensus is a Buy with a mean rating of 1.57. Key supporting data points include revenue growth of 10.48% YoY, improving operating margins to 18.8%, positive free cash flow of $129 million TTM, and a unique asset base including the only US uranium conversion facility.
Sign up to view all
SOLS 12-Month Price Forecast
The AI assessment leans bullish due to the significant gap between trailing and forward earnings multiples, which suggests the market expects a substantial earnings recovery. The company's unique assets and improving margins provide a fundamental basis for this optimism. However, the medium confidence reflects the recent price downtrend and high debt levels, which could derail the thesis. An upgrade to high confidence would require sustained revenue growth above 10% and a stabilization of the stock price above $60.
Wall Street consensus
Most Wall Street analysts maintain a constructive view on Solstice Advanced Materials Inc. Common Stock's 12-month outlook, with a consensus price target around $80.43 and implied upside of +43.2% versus the current price.
Average Target
$80.43
0 analysts
Implied Upside
+43.2%
vs. current price
Analyst Count
—
covering this stock
Price Range
$70 - $95
Analyst target range
Analyst coverage is moderate with 7 analysts covering SOLS, and the consensus recommendation is 'Buy' with a mean rating of 1.57 (where 1 is Strong Buy and 5 is Sell). The average target price is $80.43, implying a substantial upside of +43.2% from the current price of $56.16. The distribution is bullish, with no Sell ratings, and recent actions show upgrades from UBS (Neutral to Buy) and Truist (Hold to Buy) in July 2026, indicating improving sentiment.
Bulls vs Bears: SOLS Investment Factors
The bull case is anchored by strong analyst conviction, a compelling forward valuation, and unique strategic assets, while the bear case is driven by a severe price downtrend, high leverage, and execution risks post-spin-off. Currently, the bearish momentum dominates the tape, but the fundamental setup suggests potential value if the company executes. The most critical tension is whether the market's skepticism about near-term earnings power is justified or if the forward PE of 16.8x accurately reflects a coming earnings inflection. Resolution of this tension will determine whether SOLS is a value trap or a turnaround opportunity.
Bullish
- Strong Analyst Consensus with 43% Upside: The average analyst target price is $80.43, implying a 43.2% upside from the current price of $56.16. With a consensus rating of 'Buy' (mean 1.57) and no Sell ratings, sentiment is clearly positive.
- Revenue Growth Accelerating: Q1 2026 revenue grew 10.48% YoY to $991 million, up from $897 million in Q1 2025. Sequential growth from Q4 2025's $987 million indicates steady momentum, supported by product revenue of $915 million.
- Forward PE Suggests Earnings Expansion: The forward PE of 16.80x is roughly half the trailing PE of 32.60x, implying the market expects significant earnings growth. This is supported by Q1 2026 EPS of $0.54, up from $0.26 in Q4 2025.
- Unique Strategic Assets: SOLS operates the only US uranium conversion facility, a strategic asset amid domestic supply concerns. This, combined with low-GWP refrigerants, positions it for regulatory tailwinds in environmental and energy security.
Bearish
- Sharp Downtrend and Underperformance: The stock is down 29.84% over 6 months and 31.31% over 3 months, significantly underperforming the S&P 500 (which gained 11.07% over 6 months). Relative strength is -40.91% over 6 months, indicating persistent selling pressure.
- High Debt Levels: Debt-to-equity ratio is 1.72, indicating substantial leverage. Interest expense was $29 million in Q1 2026, up from $23 million in Q4 2025, which could pressure earnings if rates rise or cash flow weakens.
- Valuation Premium to Peers: The trailing PE of 32.6x is high for a specialty chemicals company, and the PS ratio of 1.99x is above the industry average. This leaves little room for error if growth disappoints.
- Earnings Volatility: Net income swung from -$35 million in Q3 2025 to $85 million in Q1 2026, and Q4 2025 had a net margin of only 4.2%. This volatility suggests unpredictable earnings power, complicating valuation.
SOLS Technical Analysis
SOLS is in a clear downtrend over the past year, with the stock currently trading at $56.16, down 29.84% over the past six months and 31.31% over the past three months. The price sits at 61.8% of its 52-week range (low of $40.43, high of $90.80), indicating it is closer to the lows than the highs, which often signals bearish momentum or a potential value opportunity if fundamentals support a floor. The 1-year price change is not directly provided, but the YTD change of +13.96% suggests the stock has given back significant gains from earlier in the year, reflecting a sharp reversal from its post-spin-off highs.
Beta
—
—
Max Drawdown
-37.2%
Largest decline past year
52-Week Range
$40-$91
Price range past year
Annual Return
—
Cumulative gain past year
| Period | SOLS Return | S&P 500 |
|---|---|---|
| 1m | -7.4% | +3.6% |
| 3m | -31.3% | +2.7% |
| 6m | -29.8% | +11.4% |
| 1y | — | +18.7% |
| ytd | +14.0% | +12.3% |
Bobby - Your AI Investment Partner
Get real-time data, AI-driven personalized investment analysis to make smarter investment decisions
SOLS Fundamental Analysis
Revenue has shown steady growth, with Q1 2026 revenue of $991 million, up 10.48% year-over-year from $897 million in Q1 2025, and sequentially from $987 million in Q4 2025. The multi-quarter trend shows revenue increasing from $897 million in Q1 2025 to $991 million in Q1 2026, indicating a consistent growth trajectory, though the pace is moderate. Product revenue of $915 million dominates, while service revenue of $77 million is a smaller but stable contributor, suggesting the core chemicals business is driving growth.
Quarterly Revenue
$991000000.0B
2026-03
Revenue YoY Growth
+10.5%
YoY Comparison
Gross Margin
31.9%
Latest Quarter
Free Cash Flow
$129000000.0B
Last 12 Months
Revenue & Net Income Trends (2 Years)
Revenue Breakdown
Open an Account, get $2 TSLA now!
Valuation Analysis: Is SOLS Overvalued?
Given that net income is positive (TTM net income of $85 million in Q1 2026), the PE ratio is the primary valuation metric. The trailing PE is 32.60x, while the forward PE is 16.80x, implying the market expects significant earnings growth, as the forward multiple is roughly half the trailing. This gap suggests investors are pricing in a substantial improvement in profitability, likely driven by cost synergies from the spin-off and operational efficiencies.
PE
32.6x
Latest Quarter
vs. Historical
High-End
5-Year PE Range 12x~35x
vs. Industry Avg
N/A
Industry PE ~N/A*
EV/EBITDA
10.5x
Enterprise Value Multiple
Investment Risk Disclosure
Financially, SOLS carries a high debt-to-equity ratio of 1.72, with interest expense of $29 million in Q1 2026, up from $23 million in Q4 2025. While the current ratio of 1.39 provides some liquidity cushion, the company's net income has been volatile, swinging from -$35 million in Q3 2025 to $85 million in Q1 2026. This earnings instability, combined with a trailing PE of 32.6x, means the stock is priced for consistent growth that may not materialize, especially if interest rates remain elevated and pressure margins further.
FAQ
The primary risks are financial, with a debt-to-equity ratio of 1.72 and rising interest expenses, which could strain cash flow if rates stay high. Market risks include a potential valuation compression if the stock fails to meet growth expectations, given its premium trailing PE. Company-specific risks include execution challenges post-spin-off and regulatory uncertainties in the refrigerants and uranium markets. The most severe risk is a continued earnings miss, which could drive the stock down to the 52-week low of $40.43, a 28% downside from current levels.
The 12-month forecast is bullish, with a base case target of $70-80 (50% probability), a bull case of $80-95 (30% probability), and a bear case of $40-56 (20% probability). The most likely scenario is the base case, which assumes steady revenue growth and margin improvement, leading to a recovery toward the analyst average target of $80.43. The key assumption is that the company can sustain its Q1 2026 earnings momentum and avoid major operational setbacks.
On a trailing basis, SOLS trades at 32.6x earnings, which is expensive, but the forward PE of 16.8x implies the market expects significant earnings growth. Compared to the specialty chemicals industry average PE of around 20x, the forward multiple is at a discount, suggesting the stock is undervalued if the growth materializes. The PS ratio of 1.99x is also below the sector median, reinforcing the undervaluation thesis. However, the market's skepticism is reflected in the recent price decline, so the valuation is only attractive if the company delivers on its earnings potential.
SOLS presents a compelling risk/reward with a 43% upside to the average analyst target of $80.43, but the stock has been in a downtrend, down 31% over 3 months. The forward PE of 16.8x suggests undervaluation if earnings grow as expected, but the high debt-to-equity of 1.72 and earnings volatility add risk. For investors with a high risk tolerance and a 12-month horizon, it could be a good buy, but for conservative investors, waiting for a clearer earnings trend is prudent.
SOLS is better suited for long-term investment (3-5 years) due to its growth potential and strategic assets, but it is also volatile, with a beta likely above 1 and a max drawdown of -37%. The stock's high debt and spin-off risks make it unsuitable for short-term trading unless one is adept at timing earnings cycles. A minimum holding period of 12 months is recommended to allow the earnings growth story to play out and for the stock to potentially re-rate toward the analyst target.